Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The erythrocytic stage of *Plasmodium* species refers to the phase in the malaria parasite’s lifecycle when it infects and multiplies within red blood cells (erythrocytes) of the vertebrate host. This stage is responsible for all clinical manifestations of malaria, including fever, chills, anemia, and complications such as cerebral malaria. Almost all current antimalarial drugs target processes unique or essential to the parasite’s intraerythrocytic development because this is when symptoms occur and transmission can be interrupted by killing gametocytes before they are taken up by mosquitoes.
Varies depending on the drug; examples include inhibition of heme detoxification, inhibition of parasite enzymes, disruption of parasite membrane function.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium spp. Erythrocytic Stage.